Molecular Partners presents the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug MP0250 at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO) in Chicago.
Molecular Partners announces its Interim Management Statement for the period ending March 31, 2018.
Molecular Partners presented preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) at the 1st European Myeloma Network Meeting in Turin.
At the AGM of Molecular Partners, the shareholders approved all motions proposed by the Board with a large majority and elected Bill Burns as new Chairman.
Molecular Partners and AstraZeneca collaborate on Molecular Partners’ ongoing phase 1b/2 clinical study of MP0250 with osimertinib (Tagrisso®) for the treatment of patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) pre-treated with osimertinib.
Molecular Partners presents new pre-clinical data from two of its pipeline candidates, MP0310 and MP0250, as well as the DARPin® toolbox at the AACR Annual Meeting 2018 in Chicago.
Molecular Partners has published the invitation to its Annual General Meeting 2018.
Molecular Partners publishes its audited Financial Results for 2017 and the company’s 2017 Annual Report.
Molecular Partners presents at the Cowen and Company 38th Annual Healthcare Conference in Boston.
Molecular Partners’ collaboration partner Allergan has exercised the third option to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners.